Dyne Therapeutics, Inc.

Since inception, the Company has funded its operations with proceeds from the sales of equity securities, and its term loan with Hercules Capital, Inc.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

The Company expects that its cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses, debt service obligations and capital expenditure requirements for at least 12 months from the issuance of these condensed consolidated financial statements.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

To continue its development efforts, the Company will need to obtain substantial additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements in order to fund its research and development and ongoing operating expenses.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

Commercial paper, certificates of deposit, and corporate debt securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

Debt On June 27, 2025 (the Closing Date ), the Company entered into a Loan and Security Agreement with Hercules (as subsequently amended, the "Loan Agreement"), in its capacity as administrative agent and collateral agent (the Agent ) and as a lender, and certain other financial institutions that from time to time become parties to the Loan Agreement as lenders (collectively, the Lenders ).

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

Certain negative covenants under the Loan Agreement limit the ability of the Company, among other things, to incur future debt, grant liens, make investments, make acquisitions, distribute dividends and sell assets, subject in each case to certain exceptions.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

(Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today reported financial results for the first quarter of 2026 and recent business highlights.

SEC original ↗Dyne Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

” “In DM1, we have reached our target of 60 participants in the registrational expansion cohort of the ACHIEVE trial of z-basivarsen.

SEC original ↗Dyne Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

No related serious TEAEs were observed in the registrational expansion cohort (REC).

SEC original ↗Dyne Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

launch of z-rostudirsen in Q1 2027, assuming the FDA grants Priority Review and approval is received on the anticipated timeline.

SEC original ↗Dyne Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

launch of z-basivarsen in Q1 2028, assuming FDA grants Priority Review and approval is received on the anticipated timeline.

SEC original ↗Dyne Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties.

SEC original ↗Dyne Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Legal Proceedings 32 Item 1A.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, fluctuations in operating results, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

The terms of any financing may adversely affect the holdings or the rights of the Company s stockholders.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026

If the Company is unable to obtain funding, the Company could be forced to delay, limit, reduce or eliminate some or all of its research and development programs, pipeline expansion or future commercialization efforts or grant rights to develop and market product candidates, which could adversely affect its business prospects.

SEC original ↗Dyne Therapeutics, Inc. — 10-Q Quarterly report10-QJul 29, 2026